Tags : Improving

Abbott Integrates its CGM Technology with Tandem’s Insulin Delivery System

Shots: The companies collaborated to develop & commercialize integrated diabetes solutions that combine Abbott’s FreeStyle Libre CGM technology with Tandem’s t:slim X2 pump to improve diabetes management In Oct’2019, the two companies collaborated to their technologies for monitoring glucose without fingersticks while the current agreement covers the technical development of device integration and its commercial […]Read More

Roche Launches v-TAC Blood Gas Digital Solution for Improving Patient

Shots: Roche reported the CE mark availability of its v-TAC digital diagnostic solution, allowing clinicians to get results for arterial blood gas values from patients with respiratory or metabolic abnormalities. The tool helps in simplifying the screening, diagnosis and monitoring of patients with respiratory compromise in the COVID-19 pandemic Roche’s v-TAC requires no specially trained […]Read More

Fitbit Collaborates with BMS-Pfizer Alliance Focusing on Improving Atrial Fibrillation

Shots: The BMS-Pfizer Alliance and Fitbit collaborate to develop educational content and guidance, supporting patients with a high risk of AFib. The companies will focus on providing information to encourage patients to have a discussion with their physicians, following the FDA clearance of AFib detection software on Fitbit devices The collaboration helps to bridge the […]Read More

Abbott and Tandem Collaborate to Explore Integrated Diabetes Solutions Improving

Shots: The companies collaborated to develop & commercialize integrated diabetes solutions combining Abbott’s FreeStyle Libre System with the Tandem’s t:slim X2 insulin pump expanding choice for the patients to manage diabetes The focus of the agreement is to combine Abbott’s and Tandem’s leadership and expertise to provide people with new ways to manage their diabetes, […]Read More

GSK Signs a Five Years Collaboration with Lyell to Develop

Shots: Lyell to apply its technologies to strengthen GSK’s cell therapy pipeline including GSK3377794 targeting the NY-ESO-1 antigen expressed along multiple cancer plus an approach to counter T cell exhaustion while increasing probability for delivering cancer therapies The focus of the agreement is to combine the GSK’s strong cell and gene therapy programmes with Lyell’s […]Read More